

REMARKS

Claims 1-18, 20, and 21 are currently pending in the application. Claim 21 has been withdrawn as drawn to non-elected subject matter. By the present communication, claims 1, 3, 10, 14, 17, and 20 are amended and new claim 22 is added. The amended claim language is supported throughout the as-filed specification, the Examples, and the claims as originally filed. No new matter has been added. In view of these amendments, 2, 5, and 6 are canceled herein without prejudice or disclaimer. After entry of the present amendment, claims 1, 3, 4, 7-18, and 20-22 will be under consideration.

Rejection Under 35 U.S.C. §112, Second Paragraph

Claims 1-18, and 20 stand rejected under 35 U.S.C. §112, second paragraph, as allegedly being indefinite.

The Examiner asserts that the term "hypomethylation" as recited in independent claims 1, 10, and 17 is a relative term, which allegedly renders the claim indefinite. Applicants respectfully disagree and submit that this term would be clear to the skilled artisan. However, without acquiescing to the reasoning offered by the Examiner, claims 1, 10, and 17 have been amended herein to recite that "hypomethylation is as compared to the half-methylation of the normally imprinted gene." Support for this amendment may be found throughout the specification, for example, at paragraph [0181]. Accordingly, reconsideration and withdrawal of this rejection are respectfully requested.

The Examiner asserts that the phrase "corresponds to" as recited in claim 14 allegedly renders the claim indefinite. Applicants respectfully disagree and submit that this term would be clear to the skilled artisan. However, without acquiescing to the reasoning offered by the Examiner, this phrase has been deleted from the claim. Accordingly, reconsideration and withdrawal of this rejection are respectfully requested.

The Examiner asserts it is unclear how claim 20 further limits claim 17, from which it depends. Applicants respectfully disagree. However, without acquiescing to the reasoning

offered by the Examiner, claim 20 has been amended herein to indicate that the method of claim 17 further comprises detecting hypomethylation of an H19 DMR. Accordingly, reconsideration and withdrawal of this rejection are respectfully requested.

Rejection Under 35 U.S.C. §112, First Paragraph

Claims 1-18, and 20 stand rejected under 35 U.S.C. §112, first paragraph as allegedly not enabled by the specification. Applicants respectfully traverse the rejection.

The Examiner acknowledges that the specification is enabling for methods in which a biallelic absence of methylation at positions 87, 90, and 106 of SEQ ID NO:1 is detected in human blood or colonic mucosal samples as correlating with LOI of the IGF2 gene in human colorectal cancer (CRC) patients and as an indicator of CRC risk in subjects. However, the Examiner asserts that the specification is not enabling for methods employing detection of any other type of hypomethylation within H19 and/or IGF2 genes as indicators of LOI of H19 and/or IGF2 or as indicators of cancer risk or for non-human subjects or other forms of cancer. Applicants respectfully disagree.

The present invention, as defined by amended claim 1, is directed to a method for identifying loss of imprinting (LOI) of the IGF2 gene in a subject with colorectal cancer, by analyzing a biological sample from the subject for hypomethylation of a differentially methylated region (DMR) of at least one of the H19 gene and the IGF2 gene and detecting hypomethylation of the DMR in the subject, wherein hypomethylation is as compared to the half-methylation of the normally imprinted gene, and wherein further the DMR of the IGF2 gene comprises SEQ ID NO:1, wherein detection of hypomethylation of the DMR in the subject correlates with loss of imprinting (LOI). Applicants submit that the amended claims are fully enabled by the specification.

The present invention is based on the discovery disclosed in the present application that hypomethylation, rather than hypermethylation, is linked to the LOI of IGF2 in colorectal cancer. In this regard, the specification provides two lines of evidence,

In CRC lines in which hypomethylation is induced artificially by DNMT1/DNMT3B double knockout, LOI is found only in the hypomethylated lines. Indeed, unmodified HCT116 cells with hypermethylation of the H19 DMR exhibit normal imprinting, even though Wilms' tumors with hypermethylation of the same sites show LOI. Furthermore, in primary human CRC, as well, LOI is linked to hypomethylation rather than hypermethylation.

Specification at paragraph [0180]. With regard to the latter line of evidence mentioned above, the present disclosure provides evidence that hypomethylation, that is, decreased methylation relative to the half-methylation status of the normally imprinted gene, of a DMR in IGF2 is associated with CRC. In Example 2, three exemplary CpG sites of a DMR upstream of exon 3 in the IGF2 gene (i.e., positions 87, 90, and 106 of SEQ ID NO:1) were examined for methylation status. The results in Table 4 indicate that of 20 CRCs informative for imprinting status of IGF2, the 12 samples with LOI all showed marked hypomethylation of the IGF2 DMR, whereas the 8 samples with normal imprinting showed the normal half-methylation pattern at the IGF2 DMR. These results are consistent with early reports describing “the first epigenetic alterations found in human cancer was hypomethylation of DNA and that CRC show global hypomethylation even in the presence of specific sites of increased DNA methylation” (specification at paragraph [0180]). Thus, it appears that it is the overall hypomethylation of this DMR, relative to the half-methylation normally imprinted gene, that is important, rather than the specific sites which are hypomethylated. Indeed, a recent report by Murrell *et al.* (PLOS One 3(3):e1849, 2008; copy attached) supports these findings. In particular, the authors evaluated the same IGF2 DMR (termed “DMR0”), including the same 3 CpG, as well as 3 others within this DMR, and found that hypomethylation was associated with LOI of IGF2.

In addition, the data provided in the applications suggest that “normal imprinting in the colon and LOI in CRC is specifically linked to the methylation status of a DMR within IGF2 and to a lesser extent to the methylation status of H19” (specification at paragraph [0181]). In particular, the results of the methylation analyses provided indicate,

bisulfite sequencing analysis of HCT116 cells, and HCT116 cells lacking DNMT1, DNMT3B, or both, revealed that in the double-knockout cells,

which showed LOI, both the H19 and IGF2 DMRs were extensively hypomethylated (FIG. 4). This hypomethylation was found in three separate double-knockout lines with LOI and in none of single-knockout or wild-type lines with normal imprinting (Table 3).

Specification at paragraph [0177]. With regard to these studies, the Examiner asserts that the specification does not establish genetically engineered cell lines examined (i.e., HCT116 cells lacking DNMT1, DNMT3B, or both) are accepted models of human disease. Applicants respectfully submit that the HCT116 cells are colorectal carcinoma cells, and as such would be recognized by the skilled artisan as relevant to the study of colorectal cancer. However, the purpose of this study was to provide further evidence of the role of hypomethylation in the LOI of IGF2. In particular, the cells were engineered to knockout one or more DNA methyltransferases to produce hypomethylation. The results showed that HCT116 cells, which show normal imprinting, undergo LOI of IGF2 after the somatic knockout of DNA methyltransferase 1 and 3B and that H19 and IGF2 DMR were extensively hypomethylated (specification at paragraph [0177]). Thus, these data support the role of hypomethylation in LOI of IGF2.

Based on the foregoing, Applicants submit that the amended claims are fully enabled by the specification. Accordingly, reconsideration and withdrawal of the rejection are respectfully requested.

In re Application of:
Andrew P. Feinberg
Application No.: 10/629,318
Filing Date: July 28, 2003
Page 10

PATENT
Attorney Docket No. JHU1900-1


CONCLUSION

Applicant submits that pending claims 1-18, and 20-22 are in condition for allowance. The Examiner is invited to contact Applicant's undersigned representative if there are any questions relating to this submission.

The Commissioner is hereby authorized to charged the total amount of \$555.00 as payment for the Three-Month Extension of Time fee, small entity, to Deposit Account No. 07-1896. The Commissioner is further authorized to charge any additional fees, or make any credits, to Deposit Account No. 07-1896 referencing the above-identified attorney docket number.

Respectfully submitted,

Date: November 2, 2009


for Lisa A. Haile, J.D., Ph.D.
Registration No. 38,347
Telephone: (858) 677-1456
Facsimile: (858) 677-1465

DLA Piper LLP (US)
4365 Executive Drive, Suite 1100
San Diego, California 92121-2133
USPTO Customer Number 28213

Attachment: Murrell et al., PLOS One 3(3):e1849, 2008

Distinct Methylation Changes at the *IGF2-H19* Locus in Congenital Growth Disorders and Cancer

Adele Murrell^{1*}, Yoko Ito^{1,3}, Gaetano Verde^{2,3}, Joanna Huddleston¹, Kathryn Woodfine¹, Margherita Cirillo Silengo⁴, Filippo Spreafico⁵, Daniela Perotti⁶, Agostina De Crescenzo^{2,3}, Angela Sparago^{2,3}, Flavia Cerrato^{2,3}, Andrea Riccio^{2,3}

1 Department of Oncology, University of Cambridge, CRUK Cambridge Research Institute, Cambridge, United Kingdom, **2** Dipartimento di Scienze Ambientali, Seconda Università di Napoli, Caserta, Italy, **3** Institute of Genetics and Biophysics "A. Buzzati Traverso", Consiglio Nazionale delle Ricerche (CNR), Naples, Italy, **4** Dipartimento di Scienze Pediatriche e dell'Adolescenza, Università di Torino, Torino, Italy, **5** Pediatric Oncology Unit, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, **6** Department of Experimental Oncology and Laboratories, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy

Abstract

Background: Differentially methylated regions (DMRs) are associated with many imprinted genes. In mice methylation at a DMR upstream of the *H19* gene known as the Imprint Control region (IC1) is acquired in the male germline and influences the methylation status of DMRs 100 kb away in the adjacent Insulin-like growth factor 2 (*Igf2*) gene through long-range interactions. In humans, germline-derived or post-zygotically acquired imprinting defects at IC1 are associated with aberrant activation or repression of *IGF2*, resulting in the congenital growth disorders Beckwith-Wiedemann (BWS) and Silver-Russell (SRS) syndromes, respectively. In Wilms tumour and colorectal cancer, biallelic expression of *IGF2* has been observed in association with loss of methylation at a DMR in *IGF2*. This DMR, known as DMR0, has been shown to be methylated on the silent maternal *IGF2* allele presumably with a role in repression. The effect of *IGF2* DMR0 methylation changes in the aetiology of BWS or SRS is unknown.

Methodology/Principal Findings: We analysed the methylation status of the DMR0 in BWS, SRS and Wilms tumour patients by conventional bisulphite sequencing and pyrosequencing. We show here that, contrary to previous reports, the *IGF2* DMR0 is actually methylated on the active paternal allele in peripheral blood and kidney. This is similar to the IC1 methylation status and is inconsistent with the proposed silencing function of the maternal *IGF2* allele. Beckwith-Wiedemann and Silver-Russell patients with IC1 methylation defects have similar methylation defects at the *IGF2* DMR0, consistent with IC1 regulating methylation at *IGF2* in *cis*. In Wilms tumour, however, methylation profiles of IC1 and *IGF2* DMR0 are indicative of methylation changes occurring on both parental alleles rather than in *cis*.

Conclusions/Significance: These results support a model in which DMR0 and IC1 have opposite susceptibilities to global hyper and hypomethylation during tumorigenesis independent of the parent of origin imprint. In contrast, during embryogenesis DMR0 is methylated or demethylated according to the germline methylation imprint at the IC1, indicating different mechanisms of imprinting loss in neoplastic and non-neoplastic cells.

Citation: Murrell A, Ito Y, Verde G, Huddleston J, Woodfine K, et al. (2008) Distinct Methylation Changes at the *IGF2-H19* Locus in Congenital Growth Disorders and Cancer. PLoS ONE 3(3): e1849. doi:10.1371/journal.pone.0001849

Editor: Suzannah Rutherford, Fred Hutchinson Cancer Research Center, United States of America

Received: December 14, 2007; **Accepted:** February 19, 2008; **Published:** March 26, 2008

Copyright: © 2008 Murrell et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by CRUK Senior Cancer Research Fellowship (A.M.) and Società Italiana di Cancerologia and Fondazione Pezcoller fellowship (F.C.) and grants from AICR (A.M.), MIUR PRIN 2005 (A.R.), Istituto Superiore di Sanità (A.R.), Associazione Italiana Ricerca sul Cancro (A.R. and D.P.), Telethon-Italia Grant No. GGP04072 (A.R.), and the Associazione Bianca Garavaglia, Busto Arsizio, Varese, Italy (D.P.).

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: amm207@cam.ac.uk

These authors contributed equally to this work.

Introduction

Aberrant imprinting of the Insulin-like growth factor 2 (*IGF2*) gene plays a role in the pathogenesis of the overgrowth disorder Beckwith-Wiedemann syndrome (BWS, OMIM#130650), the growth-restriction condition Silver-Russell syndrome (SRS, OMIM#180860), as well as various human cancers including Wilms tumour, rhabdomyosarcoma, hepatoblastoma, colorectal and breast carcinomas [1–6].

Mouse models have been used to demonstrate that the imprinted expression of the closely linked *Igf2* and *H19* genes is

controlled by specific differentially methylated regions (DMRs) [7–10]. One of these DMRs (the *H19* DMR) is located 5' of the *H19* promoter is methylated on the paternal chromosome and is known as the imprinting control region IC1 because it functions as an insulator mediated by the CTCF binding factor (CTCF) [11–14]. Deletion of the maternal IC1 results in activation of the normally silent maternal *Igf2* allele and in down-regulation of *H19* [9]. In addition, a hierarchical relationship between methylation at IC1 and *Igf2* exists such that deletion or mutation within the IC1 also results in methylation changes in DMRs within the *Igf2* gene [15]. We have previously shown that IC1 actually interacts with

Igf2 DMRs in a mutually exclusive and parent of origin specific manner influenced by CTCF binding and DNA methylation [16,17]. The application of this model to the human has been hampered by differences in the genomic organisation of *IGF2* DMRs in mouse and human. Specifically, *IGF2* DMR0, located 5' to the main *IGF2* promoters is methylated on the maternal allele only in placentas in the mouse [18], but has differential methylation in all tissues in humans [19]. Methylation of the DMR0 on the maternal *IGF2* allele was inferred using cell lines derived from a BWS patient with paternal uniparental disomy at 11p15.5 loci (UPD) [19] and in Wilms tumour kidney patients with loss of heterozygosity of the maternal allele [20]. Methylation analysis of the *IGF2* DMR0 has been carried out in many cancer studies following the demonstration that hypomethylation of this DMR is associated with loss of imprinting in Wilms tumour [20] and colorectal cancer [21]. The current interpretation of these results is that loss of methylation at the *IGF2* DMR0 plays a role in reactivation of the silent maternal allele [21].

The molecular basis of BWS is heterogeneous with 5% of patients exhibiting gain of methylation at IC1 with biallelic activation of *IGF2* and biallelic silencing of *H19*. Another group of BWS patients has normal IC1 methylation but abnormal methylation at IC2, a maternally methylated imprinting control region within the *KCNQ1* and *KCNQ1OT1* gene cluster which seems to operate independent of *IGF2* and *H19* [2]. BWS patients with IC1 defects have a particularly high predisposition to developing Wilms tumour, while those patients with IC2 defects are apparently more at risk for other tumours [2,22]. Hypermethylation at the IC1 is also a frequent feature in non-syndromic Wilms tumour patients which together with the distinct tumour predisposition profiles in BWS patients suggest that similar epigenetic defects lead to soma-wide overgrowth and cancer. SRS also has a complex heterogeneous molecular aetiology and a subset of individuals has loss of methylation at IC1 with biallelic silencing of *IGF2* and biallelic activation of *H19* [6].

To date there have been no reports on the methylation status of the *IGF2* DMR0 region in BWS and SRS patients and it is not known to what extent the proposed silencing function of this DMR contributes to the aetiology of BWS and SRS. We therefore examined parent of origin methylation at the DMR0 in various subtypes of BWS and SRS patients and also in a cohort of Wilms tumour samples. Our results indicate that the active paternal *IGF2* allele is methylated at the DMR0 in *cis* with *H19* methylation in normal individuals and that in SRS and BWS the DMR0 and IC1 have similar methylation abnormalities. In contrast, in Wilms tumour samples DMR0 methylation is negatively correlated with IC1 methylation. These results imply *IGF2* imprinting defects in congenital growth disorders and Wilms tumours arise through different epigenetic mechanisms.

Results

IGF2 DMR0 methylation status in BWS and SRS patients

We examined the methylation status of DMR0 in peripheral blood leukocyte DNA derived from BWS patients with IC1 hypermethylation ($n = 7$), IC2 hypomethylation ($n = 37$) or normal methylation at both IC1 and IC2 ($n = 27$) and SRS patients with IC1 hypomethylation ($n = 2$), using bisulphite and pyrosequencing analysis. The region analysed is shown in figure 1A. To our surprise, 6/7 BWS patients with hypermethylation at IC1 also had hypermethylation at DMR0 (Median methylation 69.2%, interquartile range (IQR) 60.5%; 75.1%) and 2/2 SRS with IC1 hypomethylation also had DMR0 hypomethylation (28.2% and 36.28%). Patients with normal

methylation at IC1 or hypomethylation at IC2 had normal methylation levels at DMR0 (Median methylation 53%; IQR 48.2%, 57.1%). These results suggest that either methylation changes in BWS and SRS were occurring in *trans* or that methylation at the DMR0 is on the paternal allele.

To distinguish between these possibilities, we examined 13 BWS patients with excess copies of paternal 11p15.5 (12 patients had paternal UPD and one patient had an 11p15.5 duplication) and two SRS patients with maternal 11p15.5 duplications. We also determined directly the parental origin of methylation at the *IGF2* DMR0 in some of our BWS and SRS patients and 6 control individuals in order to confirm our findings. The patients with maternal duplication had reduced methylation levels (44%), while all the paternal UPD and the paternal duplication patients had hypermethylation (Median methylation 60.2%; IQR 56.1%, 64.3%), Fig. 1B). In all informative families we were able to confirm that the paternal allele was preferentially methylated at the DMR0 (particularly the CpGs 15–17) in *cis* with methylation at the IC1 (Fig. 1C and Fig. S1). These results therefore suggest that methylation at the IC1 influences methylation at the *IGF2* DMR0. BWS and SRS cases with methylation defects at the IC1 acquire the same methylation defect at the DMR0 in the germline or early fetal development such that the maternal *IGF2* allele gains methylation and is activated (BWS) or the paternal allele fails to become methylated and is silenced (SRS). These allele-specific methylation changes have the effect of an imprint switch so that both alleles look like either a paternal allele (BWS) or a maternal allele (SRS). Pyrosequencing results were verified by bisulphite sequencing (Fig. S1).

IGF2 methylation analysis in Wilms Tumour samples

We analysed DMR0 methylation in two Wilms tumour patients that had arisen in individuals affected by BWS and a series of non-syndromic Wilms tumour patients. One of the BWS patients had constitutional hypermethylation at IC1, the other had paternal UPD. The non-syndromic Wilms tumour patients comprised of individuals that had tumour-specific IC1 hypermethylation ($n = 10$), 11p15.5 LOH with loss of the maternal allele ($n = 13$) or normal methylation ($n = 10$) at the IC1. Remarkably, all tumours with hypermethylation at IC1 and most of those with LOH, including those arisen in individuals affected by BWS, showed reduced methylation at DMR0 (Median methylation 24.8%, IQR 16.52, 34.9), while those with normal IC1 methylation had normal DMR0 methylation (Median methylation 45.1%, IQR 34.2; 52.3) (Fig. 2A–B). Indeed, a significant inverse correlation (Pearson $r = 0.7118$, CI -0.718–0.4146) could be shown between DMR0 and IC1 methylation levels in Wilms tumour patient (Fig. 2C). As in blood leukocytes, adjacent non tumour tissue showed predominant methylation of the paternal allele (Fig. 2D and data not shown). These results show distinct epigenetic changes in Wilms tumour compared to congenital growth disorders.

Discussion

The results of our genetic studies demonstrate that DMR0 is methylated on the paternal allele contradicting the conclusions of two previous studies which have reported that DMR0 methylation is on the maternal allele [19,20]. In the first report methylation was investigated for the entire *IGF2* gene in Wilms tumour samples with and without loss of imprinting [20]. In this study, differential methylation at the DMR0 region was shown in normal kidney and in tumours with monoallelic expression, whereas tumours with loss of imprinting, were hypomethylated [20]. The CpGs that we




Figure 1. IGF2 DMR0 Methylation levels in Beckwith-Wiedemann Syndrome (BWS) and Silver-Russell Syndrome (SRS) patients. A. Location of DMR0 within the *IGF2* gene relative to the paternally methylated imprinting control region IC1 which is upstream of *H19*. Pyrosequencing was used to analyse methylation at six CpGs within the DMR0 region (NCBI 36: 11, 2125904–2126160, containing SNP rs3741210). Bisulphite (BSQ) and pyrosequencing (PSQ) primer positions are as indicated. This region contains the CpGs (numbered 15,16,17) marked in grey which have previously been published to be hypomethylated in Colorectal cancer [21]. Vertical lines indicate *MspI/HpaII* sites in the DMR0. **B.** Box plot showing medians, IQR, max. and min. values for *IGF2* DMR0 methylation levels as measured by pyrosequencing of bisulphite converted DNA obtained from peripheral blood samples from BWS and SRS patients. Methylation percentages reflect the proportion of bisulphite converted cytosines at the CpGs measured in the assay. Normal methylation levels for imprinted DMRs are 45–55% (see C). Categories of BWS patients included those with: no imprinting defect at the IC1 region and the IC2 region (NM); low methylation (LM) at the IC2 (IC2-LM); increased paternal 11p15 through paternal duplication or uniparental disomy (pUPD); and hypermethylation at IC1 (IC1-HM). SRS patients included two each of maternal duplication of 11p15 (Mat Dup) and hypomethylation at IC1 (IC1-LM). BWS with hypermethylation at the IC1, also have hypermethylation at DMR0, while SRS with hypomethylation IC1 have hypomethylation at DMR0. **C.** Parent of origin specific methylation in normal, BWS and SRS patients. The BWS and SRS patients have imprinting defects at IC1. Bisulphite converted DNA was amplified with allele-specific primers for the rs3741210 polymorphism in *IGF2* DMR0 prior to pyrosequencing for methylation. The T allele is shown by squares and C alleles shown by triangles in the plots. Circles show the percentage of total methylation of the CpGs assayed. The paternal allele is more methylated at DMR0 than the maternal allele. Both alleles are hypermethylated in BWS and both alleles are hypomethylated in SRS. doi:10.1371/journal.pone.0001849.g001

analysed in our methylation assays were also examined by these authors using *MspI/HpaII* restriction analysis (Figure 1) and the region is spanned by probe 9 in figures 1 and 3 in [20]. In four cases with loss of heterozygosity of 11p15.5 where the maternal allele was lost, the retained paternal allele was found to be unmethylated and thus the maternal allele was inferred to be the normally methylated allele [20]. We examined 13 cases with LOH and showed similar hypomethylation patterns, which suggests that cells with LOH are inclined to methylation changes at the DMR0 as a result of being tumours. The second study to report that DMR0 is maternally methylated characterised novel transcripts of *IGF2* during development. These authors examined a cell line established from pUPD patient and found that the DMR0 was hypomethylated [19]. We have found that DMR0 tends to be demethylated in hybridoma cell lines with a single human chromosome 11, regardless of parental origin (unpublished observation) and assume that this may be a cell culture phenomenon.

The function of DMR0 is still unknown. It has been postulated that the role of DMR0 methylation is to maintain silencing on the maternal *IGF2* allele. However, the knowledge that the parental origin of *IGF2* DMR0 methylation is paternal eliminates a role in methylation-mediated repression of the maternal *IGF2* allele. Indeed rather than acting as an autonomous regulator of imprinting, our results suggest that the DMR0 methylation is influenced by IC1 methylation in non-neoplastic cells. Thus during embryogenesis, parent of origin specific methylation patterns at the human *IGF2-H19* locus are established *in cis* similar to observations in mice [15].

In mice where CTCF sites have been mutated, the exclusion of CTCF from the maternal IC1 has resulted in methylation of the IC1 [23] and *Igf2* DMRs [16]. Furthermore, in adult mouse choroid plexus, a brain tissue in which *Igf2* is expressed from both alleles and *H19* is not expressed, IC1 and the *Igf2* DMRs are methylated on both parental chromosomes [24]. We show here that aberrant gain or loss of methylation at the IC1 is coupled to the same methylation change at *IGF2* DMR0. The main difference is that mice have a DMR1 and a placenta specific DMR0, whereas in humans, DMR1 is lacking and the DMR0 seems to behave more similar to mouse DMR1. The ultimate effect of IC1 influencing *IGF2* methylation is that epimutation of IC1 has the consequence of both parental alleles displaying a paternal imprint in the case of BWS or a maternal imprint in the case of SRS (Fig. 3).

If long-range interactions between DMRs at this locus are similar in mice and humans, this would explain the imprinting defects that are found in the overgrowth disorders BWS and SRS. However, the imprinting defects in Wilms tumour remain difficult

to reconcile with enhancer competition and long-range DMR interaction models. In our analysis of this selected group of Wilms tumour patients, methylation at the DMR0 is lost on the paternal allele, while IC1 gains methylation on the maternal allele. DMR0 methylation levels are particularly low in some of the tumours, indicating an almost complete eradication of methylation at this site probably from both alleles (Fig. 2A C). Epigenetic reprogramming thus occurs on both parental chromosomes rather than *in cis*, indicating that different mechanisms control *IGF2* imprinting in neoplastic and non-neoplastic cells (Fig. 3). Somewhat IC1 hypermethylation in BWS predisposes to Wilms tumour and similar epigenetic changes occurs in the kidney as pre-neoplastic events in Wilms tumorigenesis [25]. It is possible that DMR0 hypomethylation is associated with a more sustained activation of *IGF2* in tumour cells as a result of alternative high level chromatin conformation promoted by tumour-specific activators.

During tumorigenesis global hypomethylation occurs in repeat rich regions, LINE and SINE elements, while CpG islands associated with promoters are subject to hypermethylation [26]. DMRs methylated in the germline and DMRs methylated in the somatic cells may differ in their ability to be reprogrammed during tumorigenesis. Further comparison of different DMRs in terms of germline versus somatic and maternally versus paternally methylated as well as genetic and epigenetic characteristics should lead to deeper understanding of epigenetic reprogramming in cancer. Prior to our studies, loss of methylation is the only described epimutation at the DMR0 in cancers, while both hyper and hypomethylation has been described at the IC1 [21,27]. Moreover, not all reports show a direct correlation between *IGF2* expression and DMR0 methylation changes at this locus and we have reported exceptions in breast cancer (Ito *et al.* submitted), while others have reported exceptions in ovarian and bladder cancer [28,29]. Those studies that do show a relationship between loss of DMR0 methylation and loss of imprinting need to be reinterpreted because the methylation at the DMR0 region is lost from the active paternal allele rather than from the silent allele.

In summary, we show three different reprogramming events occurring at the *IGF2-H19* locus and associated with imprinting loss in BWS, SRS and Wilms Tumour. In the growth disorders, germline allele-specific methylation changes have the effect of an imprint switch so that both alleles look like either a paternal allele (BWS) or a maternal allele (SRS) while in cancer both parental marks are lost and reprogrammed. Our findings demonstrate that loss of *IGF2* imprinting is a complex phenomenon that occurs with different mechanisms in human disease, probably reflecting different molecular causes and responses.




Figure 2. Methylation levels at the IGF2 DMR0 region in Wilms tumour patients. **A**, Box plot showing medians, IQR, max. and min. values for IGF2 DMR0 methylation levels as measured by pyrosequencing of peripheral blood (open box), normal kidney (hatched box) and tumour biopsies (grey box) from Wilms Tumour patients that do not have BWS. Methylation percentages reflect the proportion of bisulphite converted cytosines at the CpGs measured in the assay. Normal methylation levels for imprinted DMRs are 45–55% (see D). Wilms Tumour patient samples include peripheral blood and tumour DNA from patients with normal methylation at IC1 in their tumours (NM); peripheral blood, normal kidney and tumour DNA samples from patients with hypomethylation of IC1 in their tumours (IC1-HM); and tumour DNA samples from patients with loss of heterozygosity (LOH) in their tumours. Strikingly, Wilms Tumour patients with hypermethylation at IC1 have hypomethylation at DMR0 in their tumours. **B** Methylation levels in peripheral blood, unaffected kidney tissue and Wilms tumour kidney tissue from two BWS patients (one with IC1 hypermethylation and one with pUPD). Both patients have hypomethylation of IGF2 DMR0 in their tumours. **C** Linear regression curve showing inverse relationship between methylation levels at the IC1 and DMR0 in Wilms Tumour. Tumours with hypermethylation at the IC1 have loss of methylation at DMR0. **D**, Peripheral blood and kidney tissue from a patient with Wilms Tumour that does not have hypermethylation at IC1. The C-allele is hypermethylated, while the T-allele is hypomethylated in both the blood and kidney—indicating similar parent of origin methylation in these tissues.

doi:10.1371/journal.pone.0001849.g002




Figure 3. Summary of IGF2 DMR0 Methylation relative to IC1 in normal, congenital growth disorders and Wilms tumour. In normal individuals, *IGF2* expression is from the paternal allele and *H19* is from the maternal allele. IC1 and DMR0 are methylated on the paternal chromosome. In BWS, the epigenotype and expression pattern of the maternal chromosome are converted to paternal and in SRS, the epigenotype and expression pattern of the paternal chromosome are converted to maternal (imprint switching). In the Wilms tumour, *IGF2* activation and *H19* silencing are associated with disruption of both maternal and paternal imprints (somatic loss of imprinting).
doi:10.1371/journal.pone.0001849.g003

Materials and Methods

Subjects

85 BWS and 3 SRS cases were recruited from different Italian Pediatric Departments and were clinically diagnosed according to the criteria described in the literature (<http://www.geneclinics.org>). The study also involved 40 Wilms Tumour patients enrolled by Paediatric Oncology Units affiliated to Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). All tumours were histologically diagnosed.

Ethical Approval

This study was approved by the ethical committees of the Second University of Naples and Istituto Nazionale Tumori, INT, Milan.

Identification of IC1 and IC2 methylation, UPD, LOH and copy number abnormalities

The DNA methylation at IC1 and IC2 was analysed by Southern blotting with methylation-sensitive restriction enzymes or COBRA, as described [2]. Three samples with IC1 hypermethylation derived from BWS patients also had inherited

microdeletions [30,31]. UPD, LOH and duplication at 11p15.5 loci were determined by microsatellite analysis, as described [32].

Analyses of DMR0 methylation

We designed a standard pyrosequencing assay for *IGF2* DMR0 region (NCBI36:11,2125904-2126160) which included six CpGs, three of which were previously reported to be hypomethylated in colorectal patients with LOI at *IGF2* [21]. The CpGs within this region are included in the DMR0 region analysed by others [19,20]. 100 ng–2 µg of genomic DNA per sample was bisulphite treated using EZ DNA methylation kit (Zymo Research). Bisulphite treated DNA was used for generating PCR amplified templates for pyrosequencing using the following forward primer: 5'-TGAGGATGGGTTTGTGTTTGGTAT3' and biotinylated reverse primer 5'-TCCITCAATCCACCCAAAATAATAT3'. 10 µL of the biotinylated PCR product was used for each sequencing assay using the following sequencing primers 5'-GGGGTGGAGGGTGTAT3' and 5'-AAAAGTTATTGGA-TATATAGT3'. Pyrosequencing was carried on PSQ HS 96 System and PyroMark MD System using Pyro Gold Reagent kits (Biotage, Uppsala, Sweden). Allele-specific pyrosequencing was carried out by replacing the above biotinylated primer with allele-

specific biotinylated primers, 5'CCCAAAATAATATCTA-TAAAAAATTCAC3', or 5'CCCAAAATAATATCTA-TAAAAAATTCAT3' which recognized the G or A allele of the rs3741210 polymorphism on the reverse strand after bisulphite conversion.

Methylation was quantified using Pyro Q-CpG Software (Biotage, Uppsala, Sweden) that calculates the ratio of converted C's (T's) to unconverted C's at each CpG and expresses this as a percentage methylation. Average methylation across the DMR0 for all 6 CpGs were calculated. Median and IQR methylation for different categories of patients were analysed using Prism Graphpad software.

We verified allele-specific methylation by conventional bisulphite sequencing of cloned PCR products in all our informative cases.

Supporting Information

Figure S1 Bisulphite sequencing analyses of IGF2 DMR0 Methylation in normal, congenital growth disorders and Wilms Tumour. IGF2 DMR0 Methylation in normal, congenital growth

References

1. Blic J, Terhal P, van den Bogaard MJ, Maas S, Hamel B, et al. (2006) Hypomethylation of the H19 gene causes not only Silver-Russell syndrome (SRS) but also isolated asymmetry or an SRS-like phenotype. *Am J Hum Genet* 78: 604–614.
2. Cooper WN, Luharia A, Evans GA, Raza H, Haire AC, et al. (2005) Molecular subtypes and phenotypic expression of Beckwith-Wiedemann syndrome. *Eur J Hum Genet* 13: 1025–1032.
3. Delaval K, Wagschal A, Feil R (2006) Epigenetic deregulation of imprinting in congenital diseases of aberrant growth. *Bioessays* 28: 453–459.
4. Feinberg AP, Tycko B (2004) The history of cancer epigenetics. *Nat Rev Cancer* 4: 143–153.
5. Netchine I, Rossignol S, Dufour MN, Azzi S, Rousseau A, et al. (2007) 11p15 imprinting center region 1 loss of methylation is a common and specific cause of typical Russell-Silver syndrome: clinical scoring system and epigenetic-phenotypic correlations. *J Clin Endocrinol Metab* 92: 3148–3154.
6. Smith AC, Choufani S, Ferreira JC, Weksberg R (2007) Growth regulation, imprinted genes, and chromosome 11p15.5. *Pediatr Res* 61: 43R–47R.
7. Constanica M, Dean W, Lopes S, Moore T, Kelsey G, et al. (2000) Deletion of a silencer element in Igf2 results in loss of imprinting independent of H19. *Nat Genet* 26: 203–206.
8. Murrell A, Heeson S, Bowden L, Constanica M, Dean W, et al. (2001) An intragenic methylated region in the imprinted Igf2 gene augments transcription. *EMBO Rep* 2: 1101–1106.
9. Thorvaldsen JL, Duran KL, Bartolomei MS (1998) Deletion of the H19 differentially methylated domain results in loss of imprinted expression of H19 and Igf2. *Genes Dev* 12: 3693–3702.
10. Thorvaldsen JL, Fedoriv AM, Nguyen S, Bartolomei MS (2006) Developmental profile of H19 differentially methylated domain (DMD) deletion alleles reveals multiple roles of the DMD in regulating allelic expression and DNA methylation at the imprinted H19/Igf2 locus. *Mol Cell Biol* 26: 1245–1258.
11. Hark AT, Schoenherr CJ, Katz DJ, Ingram RS, Levorse JM, et al. (2000) CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. *Nature* 405: 486–489.
12. Bell AC, Felsenfeld G (2000) Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene. *Nature* 405: 482–485.
13. Kanduri C, Pant V, Loukinov D, Pugacheva E, Qi CF, et al. (2000) Functional association of CTCF with the insulator upstream of the H19 gene is parent of origin-specific and methylation-sensitive. *Curr Biol* 10: 853–856.
14. Szabo P, Tang SH, Rentsendorj A, Pfeifer GP, Mann JR (2000) Maternal-specific footprints at putative CTCF sites in the H19 imprinting control region give evidence for insulator function. *Curr Biol* 10: 607–610.
15. Lopes S, Lewis A, Hajkova P, Dean W, Oswald J, et al. (2003) Epigenetic modifications in an imprinting cluster are controlled by a hierarchy of DMRs suggesting long-range chromatin interactions. *Hum Mol Genet* 12: 295–305.
16. Kurukuti S, Tiwari VK, Tavoosidana G, Pugacheva E, Murrell A, et al. (2006) CTCF binding at the H19 imprinting control region mediates maternally inherited higher-order chromatin conformation to restrict enhancer access to Igf2. *Proc Natl Acad Sci U S A* 103: 10684–10689.
17. Murrell A, Heeson S, Reik W (2004) Interaction between differentially methylated regions partitions the imprinted genes Igf2 and H19 into parent-specific chromatin loops. *Nat Genet* 36: 889–893.
18. Moore T, Constanica M, Zubair M, Bailleul B, Feil R, et al. (1997) Multiple imprinted sense and antisense transcripts, differential methylation and tandem repeats in a putative imprinting control region upstream of mouse Igf2. *Proc Natl Acad Sci U S A* 94: 12509–12514.
19. Monk D, Sanches R, Arnaud P, Apostolidou S, Hills FA, et al. (2006) Imprinting of IGF2 P0 transcript and novel alternatively spliced INS-IGF2 isoforms show differences between mouse and human. *Hum Mol Genet* 15: 1259–1269.
20. Sullivan MJ, Taniguchi T, Jhee A, Kerr N, Reeve AE (1999) Relaxation of IGF2 imprinting in Wilms tumours associated with specific changes in IGF2 methylation. *Oncogene* 18: 7527–7534.
21. Cui H, Onyango P, Brandenburg S, Wu Y, Hsieh CL, et al. (2002) Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. *Cancer Res* 62: 6442–6446.
22. Weksberg R, Nishikawa J, Caluseriu O, Fei YL, Shuman C, et al. (2001) Tumor development in the Beckwith-Wiedemann syndrome is associated with a variety of constitutional molecular 11p15 alterations including imprinting defects of KCNQ1OT1. *Hum Mol Genet* 10: 2989–3000.
23. Pant V, Kurukuti S, Pugacheva E, Shamsuddin S, Mariano P, et al. (2004) Mutation of a single CTCF target site within the H19 imprinting control region leads to loss of Igf2 imprinting and complex patterns of de novo methylation upon maternal inheritance. *Mol Cell Biol* 24: 3497–3504.
24. Feil R, Walter J, Allen ND, Reik W (1994) Developmental control of allelic methylation in the imprinted mouse Igf2 and H19 genes. *Development* 120: 2933–2943.
25. Okamoto K, Morison IM, Taniguchi T, Reeve AE (1997) Epigenetic changes at the insulin-like growth factor II/H19 locus in developing kidney is an early event in Wilms tumorigenesis. *Proc Natl Acad Sci U S A* 94: 5367–5371.
26. Esteller M, Herman JG (2002) Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. *J Pathol* 196: 1–7.
27. Ulaner GA, Vu TH, Li T, Hu JF, Yao XM, et al. (2003) Loss of imprinting of IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site. *Hum Mol Genet* 12: 535–549.
28. Murphy SK, Huang Z, Wen Y, Spillman MA, Whitaker RS, et al. (2006) Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer. *Mol Cancer Res* 4: 283–292.
29. Byun HM, Wong HL, Birnstein EA, Wolff EM, Liang G, et al. (2007) Examination of IGF2 and H19 loss of imprinting in bladder cancer. *Cancer Res* 67: 10753–10758.
30. Sparago A, Cerrato F, Vernucci M, Ferrero GB, Silengo MC, et al. (2004) Microdeletions in the human H19 DMR result in loss of IGF2 imprinting and Beckwith-Wiedemann syndrome. *Nat Genet* 36: 958–960.
31. Sparago A, Russo S, Cerrato F, Ferraiuolo S, Castorina P, et al. (2007) Mechanisms causing imprinting defects in familial Beckwith-Wiedemann syndrome with Wilms' tumour. *Hum Mol Genet* 16: 254–264.
32. Cooper MJ, Fischer M, Komitowski D, Shevelov A, Schulze E, et al. (1996) Developmentally imprinted genes as markers for bladder tumor progression. *J Urol* 155: 2120–2127.

Acknowledgments

We thank the contribution of the AIEOP Wilms Tumour Scientific Committee and all the patients and their families for their participation to this study.

Author Contributions

Conceived and designed the experiments: AM AR. Performed the experiments: JH KW YI GV AS FC. Analyzed the data: AM YI. Contributed reagents/materials/analysis tools: AM AR MS FS DP AD. Wrote the paper: AM AR.